Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA weighs whether to publicize inspection reports

This article was originally published in The Silver Sheet

Executive Summary

FDA is seeking input via its Transparency Blog about whether it should publicly disclose key findings from FDA-483 inspection report forms. The reports typically are not made public. Processing Freedom of Information Act requests for the reports can take a long time because of the need to redact confidential trade secret information, the agency notes. FDA says the reports could be redesigned to separate out a summary or key-findings page that could quickly be made publicly available. The blog is found at http://fdatransparencyblog.fda.gov
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT036433

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel